

Dr John Brown joins SingVax Board as Chairman

Expanded Board positions SingVax for further growth

14 August, 2006, Singapore – SingVax Pte Ltd, a vaccine development company, has appointed Dr John Brown as Chairman of the Board of Directors (BoD). Dr Brown has extensive experience in the biotechnology sector, joining Acambis (a FTSE250 biotech company) in 1995 and leading it from early-stage to profitability. Since resigning from Acambis as CEO at the beginning of 2004, Dr Brown has taken on a number of non-executive Board positions including Ardana plc, Protherics plc, Vectura Group plc and until recently Cambridge Antibody Technology plc, prior to its successful acquisition by AstraZeneca.

Douglas Thomson, SingVax CEO said, “John’s appointment as Chairman is a tremendous endorsement of SingVax’s progress to date. John’s experience and guidance will help us immensely in our continued growth and development.”

John Brown said, “I am excited to be joining SingVax which is focused on becoming a major vaccine player in the Asia-Pacific region. I very much look forward to working with the Board and management to deliver on the business strategy.”

Continuing scientific excellence

In addition to a world-class BoD to guide business strategy, SingVax has put in place a distinguished Scientific Advisory Board (SAB) comprised of local and international experts in the fields of virology, immunology and vaccinology. Led by Prof David Rowlands, SingVax’s SAB will ensure that the company continues to achieve scientific excellence in its vaccine development programmes.

SingVax focuses on developing prophylactic vaccines for infectious diseases prevalent in the Asia Pacific region. SingVax currently has two products in the pipeline, a Japanese Encephalitis (JE) vaccine for the prevention of JE virus



infection and an Enterovirus 71 (EV71) vaccine for the prevention of Hand, Foot and Mouth Disease (HFMD). In Singapore, there were 7887¹ reported cases of HFMD within the first six months of 2006. The market potential for a JE vaccine is estimated at US\$ 250 million, while for an EV71 vaccine, it is estimated at US\$ 150 million. More information on the development of these two vaccines at SingVax can be found at www.singvax.com

-- end --

About SingVax

Launched in May 2005, SingVax is a vaccine development company that focuses on developing prophylactic vaccines for infectious diseases prevalent in humans in the Asia Pacific region. SingVax is building up its in-house vaccine development infrastructure and currently has two products in development; a Japanese Encephalitis vaccine, and an Enterovirus 71 (EV71) vaccine for the prevention of Hand, Foot and Mouth Disease. SingVax has received investments from Bio*One Capital, a leading fund management company for biomedical sciences.

For further information, please contact
SingVax Pte Ltd
11 Biopolis Way, Helios,
#04-03/04,
Singapore, 138667
info@singvax.com

Media release reference number: 507

Media enquiries may be directed to:

Asia Pacific media

Chan Yiu Lin
Greener Grass Communications
Tel: (65) 9-7655897
Fax: (65) 67779363
Email: yiulin@starhub.net.sg

US and European media

Katja Stout, Gemma Bradley
Northbank Communications
Tel: 020 30087558
Fax: 020 78868151
Email: k.stout@northbankcommunications.com

¹ Published by the Communicable Disease Surveillance Branch, Ministry of Health Singapore.